Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
本导基因 logo — 研发最好的基因治疗递送技术

本导基因

研发最好的基因治疗递送技术

Founded 2018 China Shanghai, China 1 employees Series B Total: $210.00M Biotechnology, Health Care +1

General Information

Company Name 本导基因
Founded Year 2018
Location China Shanghai, China
Employees 1
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with 本导基因. To contact 本导基因, visit bdgenetherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About 本导基因

Shanghai BDgene Technology Co., Ltd., operating under the name 本导基因 (BDgene), is a leading innovator in gene editing delivery technology and gene therapy. Established in 2018, the company boasts a team of top-notch scientists, industrial experts with international pharmaceutical backgrounds, and preclinical drug evaluation specialists. BDgene's consultant team comprises authoritative industry experts, clinicians from Grade III Level A hospitals, gene therapy and immunology experts from top 100 universities, and seasoned managers from listed pharmaceutical companies. BDgene's international leading innovative technology platform, BDlenti and BDmRNA, has attracted widespread attention from domestic and foreign research institutions and pharmaceutical companies, positioning the company as a top-tier biopharmaceutical enterprise. With a focus on addressing indications such as HSK, thalassemia, and wAMD, BDgene has secured a remarkable CNY200.00M Series B investment on 27 June 2023. The investment was led by Sunland Fund, Tongde Capital, Chunhe Capital, Penglai Capital, and Longpan Investment. Operating from China, BDgene's commitment to developing cutting-edge gene therapy delivery techniques solidifies its position as a noteworthy player in the biotechnology, healthcare, and pharmaceutical industries.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B CNY200.00M 5
Sunland Fund Tongde Capital
Sunland Fund, Tongde Capital +3
27 Jun 2023
Angel Round CNY10.00M 1
Keytone Ventures
Keytone Ventures
22 Jun 2020

本导基因 Alternatives & Competitors

本导基因 vs
Citoxlab, a Charles River Company
Citoxlab, a Charles River Company France

A Charles River Company

151 employees
Biotechnology, Health Care

FAQ About 本导基因

研发最好的基因治疗递送技术
本导基因 was founded in 2018.
本导基因 is headquartered in Shanghai, China.
本导基因 operates in Biotechnology, Health Care and Pharmaceutical.
本导基因 has approximately 1 employees.
本导基因 has completed 2 funding rounds, raising a total of $210.00M. The latest funding stage is Series B.
Top alternatives and competitors to 本导基因 include Citoxlab, a Charles River Company. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
本导基因 and Citoxlab, a Charles River Company are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for 本导基因, https://bouncewatch.com/company/-165, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes